United Therapeutics Net Worth
United Therapeutics Net Worth Breakdown | UTHR |
United Therapeutics Net Worth Analysis
United Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including United Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of United Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform United Therapeutics' net worth analysis. One common approach is to calculate United Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares United Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing United Therapeutics' net worth. This approach calculates the present value of United Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of United Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate United Therapeutics' net worth. This involves comparing United Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into United Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if United Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding United Therapeutics' net worth research are outlined below:
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Should You Invest in the Invesco Biotechnology Genome ETF |
United Therapeutics Quarterly Good Will |
|
United Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in United Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to United Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know United Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. United Therapeutics' institutional investor refers to the entity that pools money to purchase United Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aqr Capital Management Llc | 2024-06-30 | 719.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 621 K | Fuller & Thaler Asset Management Inc | 2024-09-30 | 568.4 K | Pacer Advisors, Inc. | 2024-06-30 | 561.8 K | Alliancebernstein L.p. | 2024-06-30 | 539.6 K | Amundi | 2024-06-30 | 473 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 438.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 434.8 K | Nuveen Asset Management, Llc | 2024-06-30 | 434.5 K | Blackrock Inc | 2024-06-30 | 5.5 M | Vanguard Group Inc | 2024-09-30 | 4.4 M |
Follow United Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 16.27 B.Market Cap |
|
Project United Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.19 | 0.20 | |
| Return On Assets | 0.14 | 0.14 | |
| Return On Equity | 0.16 | 0.17 |
When accessing United Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures United Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of United Therapeutics' profitability and make more informed investment decisions.
Evaluate United Therapeutics' management efficiency
United Therapeutics has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1881 %, meaning that it created $0.1881 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 11/22/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 127.88 | 134.27 | |
| Tangible Book Value Per Share | 125.44 | 131.71 | |
| Enterprise Value Over EBITDA | 7.05 | 10.85 | |
| Price Book Value Ratio | 1.72 | 1.63 | |
| Enterprise Value Multiple | 7.05 | 10.85 | |
| Price Fair Value | 1.72 | 1.63 | |
| Enterprise Value | 11.2 B | 11.8 B |
Examining the leadership quality of United Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 4.7809 | Revenue 2.8 B | Quarterly Revenue Growth 0.229 | Revenue Per Share 60.245 | Return On Equity 0.1881 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific United Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on United Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases United Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
United Therapeutics Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 30th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 16th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
United Therapeutics Earnings per Share Projection vs Actual
United Therapeutics Corporate Management
| Holly Hobson | Associate Resources | Profile | |
| JD MBA | Chairman Founder | Profile | |
| Gil Golden | Senior Officer | Profile | |
| Dewey CFA | Head Relations | Profile | |
| Kevin Gray | Senior Logistics | Profile |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.